Abstract Submission Guidelines

Time Table
-
Submission Regulations
-
-
- Abstract submission deadline for ISRO 2023 is on January 12, 2023.
- Abstracts must be submitted online via the http://submit.iscocongress.com.
- In case of abstract withdrawal, please submit your requests in writing via email to farazmand@iscocongress.com by January 18, 2023, with your submission ID number(s).
- For any questions regarding the online submission process, please email farazmand@iscocongress.com.
-
-
Aim and Scope
3.1. Clinical abstracts:
-
-
- Breast cancer
- CNS tumors
- Cancer management in COVID-19 era
- Cancer screening
- Endocrine and neuroendocrine tumors
- Gastrointestinal cancers
- Genitourinary cancers
- Gynecology cancers
- Head and neck cancers
- Hematological malignancies
- Lung cancers
- Palliative care
- Psyco-oncology
- Pediatric tumors
- Sarcoma
- Skin cancers
-
3.2. Physics abstracts:
3.3. Radiobiology abstracts:
-
-
- Normal tissue radiobiology
- Tumor radiobiology
- Immuno-radiobiology
- Microenvironment
-
3.4. RTT abstracts:
-
Criteria for acceptance
4.1. Originality:
By submitting an abstract intended for presentation at ISRO 2023, the first author (= presenter) warrants that the materials have not been previously published in any publication (in peer review setting) before February 15, 2023.
4.2. Accepted manuscript formats
-
-
- Original research
- Systematic review
- Meta-analysis
- We will not consider:
- Reviews
- Case reports/case series
- Hypothesis or proposal papers
- Letters, commentaries, or essays
- Opinion pieces
- Policy papers
- Clinical practice guidelines
- Any other type of secondary literature
- Monographs
-
4.3. Abstract structure
-
-
- Author names and affiliations should not be present in the abstract title and abstract content as the abstract must be blinded for review.
- The title of the abstract should include significant keywords that reflect the content of the abstract
- Abstracts must not exceed 350 words. Deduct 50 words for each table, graphs or figures included. For example, with two figures, the maximum word count is 250.
- Images are not permitted as they do not reproduce well. Brief and clear tables, graphs, and figures are accepted (maximum of 1 page on US Letter, 8.5 x 11-inch paper).
- The abstract is presented in an intelligible fashion and is written in standard English
- The abstract must include the main headings of Background and Objectives, Methods, Results, and Conclusions
- Methods cover the main experiments and analysis (if any)
- Results cover the findings on primary (and secondary, if any) objective
- Conclusions are presented in an appropriate fashion and are supported by the data
- Use generic terms for drug names
- Standard abbreviations may be used without definition. Nonstandard abbreviations should be kept to a minimum and placed in parentheses after the first use of the word or phrase
- Use International System (SI) for units
-
-
Review Process
-
-
- Each abstract will be blinded and scored by up to two reviewers.
- The reviewers are selected based on the abstract category (clinical, physics, radiobiology, RTT)
- Abstracts will be accepted on the basis of scientific merit and originality.
- Overall, bear in mind that your abstract will be rated according to the following criteria:
- is the design of the study valid?
- are the methods appropriate?
- what is the significance of the results?
-